Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FXS4640
- Development stage
- Phase 1
- Lead developer
- Fosun Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FXS4640 (formerly known as XS-03) is an orally administered, small molecule inhibitor of polo-like kinase 1 (PLK1) being developed by Fosun Pharma and its subsidiary Jiangsu Xingsheng Xinhui Pharmaceutical, in collaboration with NovaOnco JS Therapeutics. PLK1 is a key regulator of mitosis, and its inhibition leads to cell cycle arrest and apoptosis. FXS4640 is designed to exploit synthetic lethality in tumors harboring RAS mutations. It is currently being evaluated in clinical trials for the treatment of advanced solid tumors and RAS-mutated metastatic colorectal cancer (mCRC) in combination with chemotherapy (FOLFOX or FOLFIRI) and bevacizumab.
02
Targets
PLK1 (Polo like kinase 1)
Beyond the preview
Go deeper on FXS4640.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FXS4640.